- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00005959
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
Phase II Trial of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated Intermediate or High Grade Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one chemotherapy drug with rituximab may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of rituximab plus combination chemotherapy in treating patients who have intermediate-grade or high-grade non-Hodgkin's lymphoma.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
OBJECTIVES: I. Determine the rate of complete response and partial response in patients with intermediate or high grade non-Hodgkin's lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). II. Determine the toxicity of this regimen in these patients. III. Determine the disease-free and overall survival, time to response, and time to disease progression in patients treated with this regimen.
OUTLINE: This is a multicenter study. Patients are stratified according to the number of risk factors (0-2 vs 3-5). Risk factors include age (no greater than 60 vs greater than 60), tumor stage (II vs III or IV), number of extranodal sites (no more than 1 vs more than 1), performance status (0-1 vs 2-4), and serum LDH level (no greater than normal vs greater than normal). Patients receive rituximab IV on day 1; cyclophosphamide, doxorubicin, and vincristine IV on day 3; and oral prednisone on days 3-7. Patients over 60 also receive filgrastim (G-CSF) subcutaneously beginning on day 4 and continuing until blood counts recover (all other patients receive G-CSF as secondary prophylaxis). Treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients who respond receive 2 more courses. Patients who have no measurable disease after 6 courses receive rituximab IV once weekly for 4 consecutive weeks. This treatment continues every 6 months for 4 courses in the absence of disease progression or unacceptable toxicity. Patients who have measurable disease after 6 courses of chemotherapy receive 2 more courses for a maximum of 8 courses of CHOP, followed by maintenance therapy with rituximab (as described above). Patients are followed every 6 months for 2 years.
PROJECTED ACCRUAL: Approximately 100 patients will be accrued for this study.
Tipo de estudio
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Alabama
-
Montgomery, Alabama, Estados Unidos, 36106
- Montgomery Cancer Center
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Burbank, California, Estados Unidos, 91505
- Providence Saint Joseph Medical Center - Burbank
-
Rancho Mirage, California, Estados Unidos, 92270
- Cancer and Blood Institute of the Desert
-
-
Florida
-
Fort Lauderdale, Florida, Estados Unidos, 33308
- Southeast Florida Hematology-Oncology Group
-
Miami, Florida, Estados Unidos, 33176
- Oncology-Hematology Group of South Florida
-
Miami Beach, Florida, Estados Unidos, 33140
- Mount Sinai Comprehensive Cancer Center
-
Pensacola, Florida, Estados Unidos, 32501
- Hematology-Oncology Associates, PA
-
-
Kansas
-
Hutchinson, Kansas, Estados Unidos, 67502
- Hutchinson Clinic, P.A.
-
-
Kentucky
-
Crestview Hills, Kentucky, Estados Unidos, 41017
- Hematology/Oncology Care Inc.
-
-
Maine
-
Scarborough, Maine, Estados Unidos, 04074
- Maine Center for Cancer Medicine and Blood Disorders
-
-
Maryland
-
Rockville, Maryland, Estados Unidos, 20850
- Associates in Oncology and Hematology
-
-
Massachusetts
-
Peabody, Massachusetts, Estados Unidos, 01960
- North Shore Cancer Center
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48202
- Henry Ford Hospital
-
Saint Joseph, Michigan, Estados Unidos, 49085
- Lakeland Medical Center - St. Joseph
-
-
Missouri
-
Rolla, Missouri, Estados Unidos, 65401
- Bond Clinic
-
Saint Louis, Missouri, Estados Unidos, 63136
- Midwest Hematology Oncology Consultants, Ltd.
-
-
New Jersey
-
Morristown, New Jersey, Estados Unidos, 07962
- Hematology Oncology Associates
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87109
- New Mexico Oncology-Hematology
-
-
New York
-
Bronx, New York, Estados Unidos, 10466
- Our Lady of Mercy Medical Center
-
Brooklyn, New York, Estados Unidos, 11235
- HemOnCare, P.C.
-
-
North Carolina
-
Hickory, North Carolina, Estados Unidos, 28603
- N.W. Carolina Oncology & Hematology, P.A.
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45219
- Oncology/Hematology Care, Inc.
-
-
Tennessee
-
Memphis, Tennessee, Estados Unidos, 38163
- University of Tennessee, Memphis
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84124
- Intermountain Hematology/Oncology Associates, Inc.
-
-
Vermont
-
Colchester, Vermont, Estados Unidos, 05446
- Vermont Center for Cancer Medicine, Inc.
-
-
Virginia
-
Richmond, Virginia, Estados Unidos, 23226
- Hematology & Oncology Associates of Virginia
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
DISEASE CHARACTERISTICS: Histologically confirmed intermediate or high grade non-Hodgkin's lymphoma Stage II, III, or IV disease B-cell where lymphoid cells are CD20 or CD19 positive No mantle cell, lymphoblastic, or peripheral T-cell non-Hodgkin's lymphoma Measurable or evaluable disease No prior treatment for lymphoma No known CNS metastases A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life expectancy: At least 12 weeks Hematopoietic: Unless documented bone marrow disease: Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: SGOT and SGPT no greater than 3 times upper limit of normal Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: No history of severe heart disease, cardiomyopathy, or congestive heart failure LVEF normal by MUGA or echocardiogram Other: Not pregnant or nursing Fertile patients must use effective contraception No active infection as defined by: Clinical syndrome consistent with a viral or bacterial infection (e.g., influenza, upper respiratory infection, urinary tract infection) OR Fever with a clinical site of infection identified OR Microbiologically documented infection, including, but not limited to, bacteremia or septicemia No known HIV positivity No known sensitivity to E. coli derivatives (e.g., asparaginase, human insulin, human growth hormone, interferon alfa-2b) No other prior malignancy within the past 5 years except surgically cured basal or squamous cell skin cancer or carcinoma in situ of the cervix No psychiatric, addictive, or other disorder that may preclude study
PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics No concurrent biologic therapy except epoetin alfa No white blood cell transfusions Chemotherapy: See Disease Characteristics No concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics No concurrent radiotherapy Surgery: At least 2 weeks since prior major surgery Other: No other concurrent investigational therapy No prophylactic antibiotics
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: Carol Brannan, BS, BSN, Amgen
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- Linfoma difuso de células grandes en adultos en estadio III
- Linfoma inmunoblástico de células grandes en adultos en estadio III
- Linfoma de Burkitt en adultos en estadio III
- linfoma folicular de grado 3 en estadio IV
- Linfoma difuso de células grandes en adultos en estadio IV
- Linfoma inmunoblástico de células grandes en adultos en estadio IV
- Linfoma de Burkitt en adultos en estadio IV
- linfoma folicular de grado 3 en estadio III
- Linfoma difuso de células pequeñas hendidas en adultos en estadio III
- Linfoma difuso de células mixtas en adultos en estadio III
- Linfoma difuso de células pequeñas hendidas en adultos en estadio IV
- Linfoma difuso de células mixtas en adultos en estadio IV
- Linfoma difuso de células pequeñas hendidas en adultos contiguos en estadio II
- Linfoma difuso de células pequeñas hendidas en adultos no contiguos en estadio II
- Linfoma difuso de células grandes en adultos no contiguos en estadio II
- Linfoma difuso de células mixtas en adultos no contiguos en estadio II
- Linfoma folicular grado 3 no contiguo en estadio II
- Linfoma de Burkitt en adultos no contiguos en estadio II
- Linfoma inmunoblástico de células grandes en adultos en estadio II no contiguo
- Linfoma de Burkitt en adultos contiguos en estadio II
- Linfoma inmunoblástico de células grandes contiguo en estadio II en adultos
- Linfoma folicular grado 3 contiguo en estadio II
- Linfoma difuso de células grandes en adultos contiguos en estadio II
- Linfoma difuso de células mixtas en adultos contiguos en estadio II
Términos MeSH relevantes adicionales
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Neoplasias
- Trastornos linfoproliferativos
- Enfermedades linfáticas
- Trastornos inmunoproliferativos
- Linfoma
- Linfoma No Hodgkin
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Agentes antiinflamatorios
- Agentes antirreumáticos
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Moduladores de tubulina
- Agentes antimitóticos
- Moduladores de mitosis
- Glucocorticoides
- Hormonas
- Hormonas, sustitutos hormonales y antagonistas hormonales
- Agentes Antineoplásicos Hormonales
- Agentes antineoplásicos, alquilantes
- Agentes alquilantes
- Agonistas mieloablativos
- Agentes antineoplásicos, fitogénicos
- Inhibidores de la topoisomerasa II
- Inhibidores de la topoisomerasa
- Agentes antineoplásicos inmunológicos
- Antibióticos, Antineoplásicos
- Ciclofosfamida
- Rituximab
- Prednisona
- Doxorrubicina
- Doxorrubicina liposomal
- Vincristina
Otros números de identificación del estudio
- CDR0000067940
- AMGEN-GCSF-990756
- NCI-V00-1593
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .